MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Axcella Therapeutics (NASDAQ: AXLA)
Organization & Developments: Axcella Therapeutics
Parents
Axcella Therapeutics (NASDAQ: AXLA)
Children
2019: Axcella Health And AXA1655 In Hepatic Encephalopathy_seekingalpha.com
2020: Axcella Health: Rough Sledding, But Still In The Game_seekingalpha.com
2021: Following Up On Axcella Health
2022: Axcella axes NASH program, 85% of staff in last-ditch focus on long COVID
2022: In Second Pipeline Pivot, Axcella Axes 85% of Staff _biospace
2022: With cash dwindling, Axcella shares look at blinded NASH data
Its development platform has created a diverse pipeline of drug assets to treat metabolic liver disease, Hepatic Encephalopathy (HE) and sickle cell disease
Jumps
Finance & Acquisitions: Axcella Therapeutics
Key People: Axcella Therapeutics